Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Meeting Abstracts

Protein-based vaccination targeting the cancer testis antigen NY-ESO-1

Jonathan Cebon, Ian Davis, Lisa Ebert, Kunle Odunsi, Theo Nicholaou, Oliver Klein and Weisan Chen
Jonathan Cebon
1Ludwig Institute for Cancer Research: Melbourne Centre for Clinical Sciences, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Davis
1Ludwig Institute for Cancer Research: Melbourne Centre for Clinical Sciences, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa Ebert
1Ludwig Institute for Cancer Research: Melbourne Centre for Clinical Sciences, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kunle Odunsi
2Roswell Park Cancer Center, Buffalo, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theo Nicholaou
1Ludwig Institute for Cancer Research: Melbourne Centre for Clinical Sciences, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver Klein
1Ludwig Institute for Cancer Research: Melbourne Centre for Clinical Sciences, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weisan Chen
1Ludwig Institute for Cancer Research: Melbourne Centre for Clinical Sciences, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2008
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The Cancer Vaccine Collaborative (CVC) has pioneered vaccine approaches against Cancer Testis (CT) antigens. These molecules are characterized by expression in a wide variety of cancer types and very limited expression in non-malignant tissues. NY-ESO-1, which has been the focus of particular interest, is highly immunogenic and frequently induces spontaneous immunity, particularly in patients with advanced metastatic disease. It is not clear whether these immune responses modify the natural history of the cancer.

Vaccine trials with NY-ESO-1 have been undertaken using peptides, proteins and genetic vaccines. These trials have been undertaken in patients with fully resected cancer as well as those with advanced metastatic disease. Key observations include: (i) a broad integrated CD4, CD8 T cell and antibody response is induced in the majority of patients vaccinated with full length NY-ESO-1 and an appropriate adjuvant, (ii) the depth and breath of this response is complex and can involve many epitopes in an individual vaccine recipient, (iii) despite only being early phase trials, some strong indications of clinical activity have emerged, particularly in patients with minimal residual disease. We are currently performing a randomized international trial with NY-ESO-1 in such patients with resected melanoma under the aegis of the CVC in Australia and UK. If improved clinical outcomes are observed, this trial will establish the clinical value of targeting such molecules.

In contrast vaccination of patients with advanced metastatic melanoma resulted in attenuated immune responses and this difference appears to be due to tumor-related factors. A variety of regulatory mechanisms appear to be in play. Using immunohistochemistry and fl ow cytometric analysis of melanoma tissue, we detected expression of the transcription factor FoxP3 in the melanoma cells themselves as well as in regulatory T lymphocytes (Treg). Expression of FoxP3 may endow tumor cells with Treg-like activity, as demonstrated by contact-dependent suppression of T cell proliferation and contribute to tumor immune suppression. Although patients with advanced cancer may have NY-ESO-1 specific immune response, the quality of these responses may be critical for determining clinical outcomes and there is emerging evidence that antigen specific Treg may recognize peptides derived from CT antigens, including NY-ESO-1. Additionally, analysis of NY-ESO-1-specific T cells in patients with advanced ovarian cancer before and after depletion of Tregs revealed that Tregs masked spontaneous and vaccine induced effector T cells. The Treg suppressed effectors were generally of higher avidity than vaccine induced effector cells. Together, the CVC trials suggest that vaccine efficacy might be enhanced by targeting regulatory mechanisms via depletion of CD25+FOXP3+ Tregs and treatment with antibody against CTLA4.

This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

 

  • Copyright © 2008 by Jonathan Cebon

References

  1. 1.
    1. Barrow C,
    2. Browning J,
    3. MacGregor D,
    4. Davis ID,
    5. Sturrock S,
    6. Jungbluth AA,
    7. Cebon J
    . Tumor Ag expression in melanoma varies according to Ag and stage. Clin Cancer Res 2006;12:764–771.pmid:16467087
    OpenUrlAbstract/FREE Full Text
  2. 2.
    1. Jackson H,
    2. Dimopoulos N,
    3. Mifsud NA,
    4. Tai TY,
    5. Chen Q,
    6. Svobodova S,
    7. Browning J,
    8. Luescher I,
    9. Stockert L,
    10. Old LJ,
    11. Davis ID,
    12. Cebon J,
    13. Chen W
    . Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor Ag NY-ESO-1. J Immunol 2006;176:5908–5917.pmid:16670298
    OpenUrlAbstract/FREE Full Text
  3. 3.
    1. Davis ID,
    2. Chen W,
    3. Jackson H,
    4. Parente P,
    5. Shackleton M,
    6. Hopkins W,
    7. Chen Q,
    8. Dimopoulos N,
    9. Luke T,
    10. Murphy R,
    11. Scott AM,
    12. Maraskovsky E,
    13. McArthur G,
    14. MacGregor D,
    15. Sturrock S,
    16. Tai TY,
    17. Green S,
    18. Cuthbertson A,
    19. Maher D,
    20. Miloradovic L,
    21. Mitchell SV,
    22. Ritter G,
    23. Jungbluth AA,
    24. Chen YT,
    25. Gnjatic S,
    26. Hoffman EW,
    27. Old LJ,
    28. Cebon JS
    . Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A 2004;101:10697–10702.pmid:15252201
    OpenUrlAbstract/FREE Full Text
  4. 4.
    1. Chen Q,
    2. Jackson H,
    3. Parente P,
    4. Luke T,
    5. Rizkalla M,
    6. Tai TY,
    7. Zhu HC,
    8. Mifsud NA,
    9. Dimopoulos N,
    10. Masterman KA,
    11. Hopkins W,
    12. Goldie H,
    13. Maraskovsky E,
    14. Green S,
    15. Miloradovic L,
    16. McCluskey J,
    17. Old LJ,
    18. Davis ID,
    19. Cebon J,
    20. Chen W
    . Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci U S A 2004;101:9363–9368.pmid:15197261
    OpenUrlAbstract/FREE Full Text
  5. 5.
    1. Svobodova S,
    2. Browning J,
    3. MacGregor D,
    4. Sturrock S,
    5. Pollara G,
    6. Azad A,
    7. Davis ID,
    8. Cebon J
    . Cancer-testis antigens are co-ordinately expressed in metastatic melanoma and are associated with poorer clinical outcomes in primary stage II melanoma disease. Cancer & HIV Vaccines 2007: Shared Lessons 2007;poster P-63.
  6. 6.
    1. Svobodova S,
    2. Pollara G,
    3. Maraskovsky E,
    4. Davis ID,
    5. Chen W,
    6. Cebon J
    . Antibody responses to the cancer antigen NY-ESO-1 identify highly immunogenic domains in melanoma patients before and after vaccination. Cancer & HIV Vaccines 2007: Shared Lessons 2007;poster P-62.
  7. 7.
    1. Ebert LM,
    2. Tan BS,
    3. Browning J,
    4. Svobodova S,
    5. Russell S,
    6. Kirkpatrick N,
    7. Gedye C,
    8. MacGregor D,
    9. Moss D,
    10. Davis ID,
    11. Cebon J,
    12. Chen W
    . The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer & HIV Vaccines 2007: Shared Lessons 2007;poster P-16.
  8. 8.
    1. Klein O,
    2. Ebert L,
    3. Nicholaou T,
    4. Browning J,
    5. Russell S,
    6. Tan BS,
    7. Zuber M,
    8. Dimopoulos N,
    9. Jackson H,
    10. Hoos A,
    11. Chen W,
    12. Davis ID,
    13. Cebon J
    . T-lymphocytes recognising melanocyte differentiation antigens mediate tumour regression induced by ipilimumab. Cancer & HIV Vaccines 2007: Shared Lessons 2007;poster P-34.
View Abstract
PreviousNext
Back to top
Cancer Immunity Archive: 8 (Suppl 1)
January 2008
Volume 8, Issue Suppl 1
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Protein-based vaccination targeting the cancer testis antigen NY-ESO-1
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Protein-based vaccination targeting the cancer testis antigen NY-ESO-1
Jonathan Cebon, Ian Davis, Lisa Ebert, Kunle Odunsi, Theo Nicholaou, Oliver Klein and Weisan Chen
Cancer Immun January 1 2008 (8) (Suppl 1) 13;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Protein-based vaccination targeting the cancer testis antigen NY-ESO-1
Jonathan Cebon, Ian Davis, Lisa Ebert, Kunle Odunsi, Theo Nicholaou, Oliver Klein and Weisan Chen
Cancer Immun January 1 2008 (8) (Suppl 1) 13;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • The collaboration for AIDS vaccine discovery: A model for accelerating research
  • Robust T-cell responses and clinical responses following long peptide vaccination against high risk HPV-16
  • Human monoclonal antibodies and analytic vaccinology
Show more Meeting Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement